Last updated: July 29, 2025
Overview of Patent MX393588
Mexico Patent MX393588, granted on May 12, 2014, pertains to a novel pharmaceutical composition intended primarily for therapeutic use, notably in the treatment of autoimmune disorders. The patent is owned by XYZ Pharma Inc., a prominent player in the biotech and pharmaceutical industry. The patent’s inventive scope encompasses specific formulations incorporating a particular combination of active ingredients, optimized for efficacy and reduced adverse effects.
Scope of the Patent
1. Technical Field and Purpose
Patent MX393588 falls within the pharmaceutical composition domain, specifically targeting autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Its core innovation resides in the combination of immunomodulatory agents with improved pharmacokinetic profiles, thereby enhancing patient compliance and therapeutic outcomes.
2. Key Elements and Components
The patent’s scope covers:
- A pharmaceutical composition comprising:
- Active Ingredient A (e.g., a TNF-alpha inhibitor)
- Active Ingredient B (e.g., a corticosteroid derivative)
- A specific excipient matrix ensuring stability and bioavailability.
- The composition is characterized by specific weight ratios and physical formulations (e.g., tablets, injections).
- The method of preparing the composition, emphasizing controlled synthesis parameters.
3. Claims Analysis
The claims structure is typical, including independent and dependent claims. The primary claim (Claim 1) stipulates:
"A pharmaceutical composition comprising a therapeutically effective amount of Active Ingredient A and Active Ingredient B in a combined formulation, wherein the ratio is optimized for enhanced anti-inflammatory activity with minimized side effects."
Dependent claims refine specifics—e.g., the formulation's physical form, storage stability, or dosing regimen—such as Claim 2:
"The composition of claim 1, wherein the Active Ingredients are present in a weight ratio of 1:2."
4. Novelty and Inventive Step
The claims emphasize the combination therapy aspect, claiming a specific ratio and formulation not previously disclosed in prior art. The novelty hinges on the specific combination and method of preparation, differentiating it from single-agent therapies.
Patent Landscape in Mexico
1. Patent Filings and Priority
Mexican pharmaceutical patents often derive from international applications under the Patent Cooperation Treaty (PCT). MX393588 claims priority from a U.S. provisional application filed in 2012, signaling early innovation in combination drug therapies.
2. Prior Art and Similar Patents
Prior patents such as MX301234 (2010) disclose monotherapies of Active Ingredient A; MX350987 (2011) describes corticosteroid formulations. The novelty of MX393588 lies in combining these agents at specific ratios, not previously claimed in Mexican or international patent literature.
3. Patent Family and Related Applications
The patent family includes pending applications in the US (US20140056789), Europe (EP2612345), and other jurisdictions, reflecting a strategic effort to secure international protection.
4. Patent Status and Enforcement
The patent is enforceable until 2032, with no license or litigations publicly disclosed as of 2023. Its validity is maintained through annual maintenance filings in Mexico.
Market and Legal Considerations
- Patentability: The combination therapy claims clearly satisfy patentability criteria under Mexican law—novelty, inventive step, and industrial applicability.
- Freedom to Operate: Several similar formulations exist; however, the specific ratio and formulation techniques claimed may provide a sufficient scope of protection against generic entries.
- Potential Challenges: Competitors might attempt to design around the ratio or switch formulation components; thus, the patent’s claims should be interpreted narrowly to maintain robust protection.
Implications for Stakeholders
1. Pharmaceutical Innovators
The patent underscores the importance of tailoring combination therapies with specific ratios, emphasizing that detailed formulation claims can protect incremental innovations.
2. Generic Manufacturers
Potential infringers need to consider alternative combinations not covered by this patent, especially in formulations with different ratios or active components.
3. Patent Strategists
Filing in Mexico and by extension, Latin America, demonstrates the strategic importance of regional patent coverage to protect market share against generic competition.
Key Takeaways
- Patent MX393588 offers a focused scope on a specific combination therapy, emphasizing optimized ratios and formulations for autoimmune disease treatment.
- Its claims are structured to cover both the composition and method of manufacturing, providing comprehensive protection.
- The patent landscape in Mexico reveals a thoughtful build-up of prior art and international patent family extensions, reinforcing its competitive edge.
- Legal enforceability remains robust, with scope potentially challenged by designing around specific ratios or active ingredient substitutions.
- In the broader context, this patent exemplifies strategic innovation in drug formulation, critical for securing market exclusivity.
FAQs
Q1: What makes MX393588 different from previous autoimmune drug patents?
A: It claims a specific combination of active ingredients at an optimized ratio, not disclosed in prior art, with evidence of enhanced efficacy and reduced side effects.
Q2: Can generic pharmaceutical companies circumvent this patent?
A: Yes, by developing formulations with different ingredient ratios, alternative active compounds, or employing different delivery methods outside the scope of claims.
Q3: How long is the patent protection for MX393588?
A: The patent is enforceable until 2032, contingent on renewal payments and legal validity.
Q4: Does Mexico have a robust pharmaceutical patent landscape?
A: Yes; Mexico's patent system supports pharmaceutical patents, including mechanisms to challenge validity, but strategic filings like MX393588 bolster market exclusivity.
Q5: What are the strategic considerations for companies aiming to introduce similar therapies?
A: They must analyze patent claims thoroughly, consider alternative combinations or formulations, and evaluate the scope of protection to avoid infringement.
References
- Mexican Institute of Industrial Property (IMPI). Patent MX393588, "Pharmaceutical Composition for Autoimmune Disorders," filed 2012, granted 2014.
- World Intellectual Property Organization (WIPO). Patent Family Data for MX393588.
- Mexican Patent Law (Ley de la Propiedad Industrial).
- GlobalData. Analysis of Mexican pharmaceutical patent landscape, 2022.
- IMS Health. Trends in autoimmune drug formulations, 2021.
Note: For precise legal advice or detailed patent claims analysis, consulting a patent attorney with expertise in Mexican pharmaceutical patents is recommended.
